National Cancer Institute

Site:	National Cancer Institute	Go to their website
Address:	Building 10, Room 4-3760 10 Center Drive
City:	Bethesda
State:	MD
Zip:	20892
Country:	USA

9 trials at this site

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Active	Rogaratinib	NCT04595747
2	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Recruiting	Active	Belzutifan	NCT04924075
	Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis	Recruiting	Active	Surgery	NCT04557969
2	Cabozantinib for Adults With Advanced Soft Tissue Sarcoma	Active, not recruiting	Closed	Cabozantinib	NCT01755195
2	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer	Completed	Closed	Guadecitabine	NCT03165721
2	Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)	Withdrawn	Closed	Selumetinib	NCT03109301
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Not yet activated	Linsitinib (OSI-906)	NCT01560260
1	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	Not yet activated	INBRX-109 + Temozolomide	NCT03715933